Background: Esophageal cancer is relatively common gastrointestinal tract malignancy with poor prognosis. The aim of the study is to conduct retrospective review of esophageal cancer patients managed by Transhiatal esophagectomy (THE). Methodology: The study was retrospective analysis of prospective collected data of esophageal cancer patients from June 2010 to June 2019. Inclusion criteria: Histologically proven carcinoma, medically fit lower third esophageal cancer. Exclusion criteria: Middle third esophageal carcinoma requiring transthoracic route, metastatic cancer, medically unfit patient, patient refusing consent for surgery. Results: 575 cases of esophageal cancer were managed in a single unit of surgery. Of these 575 cases, Transhiatal esophagectomy was done in 69 patients. Mean age of the patients was 58 years. Male to female ratio was 15:54. THE alone was done in 18 (25.7%), THE + adjuvant chemotherapy in 24 (34.3%), THE + adjuvant radiotherapy in 12 (17.1%), THE + neoadjuvant chemotherapy 6 (8.6%), THE + neoadjuvant chemoradiotherapy 9 (12.9%). The overall morbidity was 40.5% (14/69). Perioperative mortality was in 5 patients (7.24%). Follow up was done for mean 26.4 months. The mean survival was 19.3 months. Conclusion: Esophagectomy is complex operation with high morbidity and potential mortality. Multimodality approach appears to be reasonable safe in managing esophageal carcinoma patients.

Keywords: Esophageal cancer; Transhiatal esophagectomy; Morbidity; Multimodality therapy.